微转移药物筛选平台显示骨肉瘤细胞系对MAP化疗的反应具有异质性
该实验室研究利用骨肉瘤球体(sarcospheres)建立药物筛选平台并评估MAP化疗。结果显示球体生长测量准确且Z'因子大于0.5符合筛选标准,不同细胞系对甲氨蝶呤的敏感性差异显著,MG-63.3和LM7球体较143B耐药超过2000倍。
要点
- 骨肉瘤球体直径和生长定量依赖于接种细胞数和细胞系。
- 间充质干细胞样球体对甲氨蝶呤的敏感性因细胞系而异,MG-63.3和LM7较143B耐药超过2000倍。
- 该平台为骨肉瘤微转移药物筛选提供了可靠且快速的方法。
核心结论
- 该研究开发并验证了用于骨肉瘤微转移进展的药物筛选平台,并揭示了骨肉瘤细胞系间的异质性。
- 这些发现似乎反映了已知的患者间异质性,并强调在测试骨肉瘤治疗药物时评估多种肿瘤模型的重要性。
研究设计与样本
- 实验室研究,利用高转移性人骨肉瘤细胞系(143B、MG-63.3和LM7)通过离心形成三维聚集体(骨肉瘤球体)以模拟微转移。
- 骨肉瘤球体成熟24小时后,在0至2天与或不与药物孵育;通过直径和体积评估大小,通过体积和刃天青还原测量生长,并在第2天计算Z'因子。
- 用单独MAP药物(0至1000 μmol/L)处理球体以确定抑制50%生长的浓度(GIC50)。
主要发现
- 骨肉瘤球体直径和0至2天的生长定量依赖于接种细胞数和所用细胞系。
- 刃天青孵育6小时(无需EDTA介导透化)后生长测量准确,且与接种细胞数和球体体积相关:143B(Spearman r=0.98;p<0.001)、MG-63.3(0.99;p<0.001)、LM7(0.98;p<0.001)。
- 所有细胞系的平均Z'因子均大于0.5,符合筛选应用的标准。
- 对MAP治疗的反应具有细胞系依赖性:MG-63.3和LM7球体对甲氨蝶呤的耐药性较143B细胞系高2000倍以上(GIC50分别为88±36 μmol/L和174±16 μmol/L vs 0.04±0.01 μmol/L;MG-63.3和LM7的p<0.001)。
- MG-63.3单层细胞对甲氨蝶呤较MG-63.3球体更敏感(GIC50=0.01±0.01 μmol/L;p<0.001),而LM7单层细胞仍保持化疗耐药(未达到GIC50)。
关键数值与推荐
- 骨肉瘤球体的平均Z'因子均大于0.5,符合筛选应用的标准。
- MG-63.3和LM7球体对甲氨蝶呤的GIC50分别为88±36 μmol/L和174±16 μmol/L,143B为0.04±0.01 μmol/L(MG-63.3和LM7的p<0.001)。
- MG-63.3单层细胞的甲氨蝶呤GIC50为0.01±0.01 μmol/L(p<0.001 vs 球体),LM7单层细胞未达到GIC50。
临床怎么用
- 作者认为,所描述的方法因针对微转移疾病进行评估,是骨肉瘤药物筛选的有前景的起点。
- 作者认为,一种可靠且快速识别新疗法的方法对于改善骨肉瘤患者停滞不前的结局至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 80% of patients with osteosarcoma harbor subclinical pulmonary micrometastases at diagnosis. Conventional chemotherapy includes methotrexate, doxorubicin, and cisplatin (MAP); however, this regimen and thus overall survival (60%-70%) have remained largely unchanged for 30 years. It therefore is necessary to identify novel therapeutics targeting the metastatic progression of osteosarcoma. QUESTIONS/PURPOSES: This laboratory study explored application of osteosarcoma spheroids (sarcospheres) for drug screening with the following purposes: (1) to characterize sarcosphere size; (2) to establish accurate measurement of sarcosphere growth; (3) to confirm sarcosphere uniformity; and (4) to apply the platform to evaluate MAP chemotherapy. METHODS: Sarcospheres were first characterized to establish accurate measurement of sarcosphere growth and uniform production. The refined platform then was applied to evaluate MAP chemotherapy to validate its use in drug screening. Sarcospheres were generated from highly metastatic human cell lines (143B, MG-63.3, and LM7) by centrifugation to form three-dimensional aggregates modeling micrometastases. Sarcospheres were matured for 24 hours and then incubated with or without drug from Days 0 to 2. Size was assessed by diameter and volume using brightfield microscopy. Growth was measured by volume and resazurin reduction in viable cells. Sarcosphere uniformity was assessed by diameter and resazurin reduction at Day 0 and the Z' factor, a measure of assay suitability for high-throughput screening, was calculated at Day 2. Sarcospheres were treated with individual MAP agents (0 to 1000 μmol/L) to determine concentrations at which 50% of growth from Days 0 to 2 was inhibited (GIC50). Cell lines resistant to MAP in sarcospheres were treated in monolayer for comparison. RESULTS: Sarcosphere diameter and growth from Days 0 to 2 were quantitatively dependent on the number of cells seeded and the cell line used. Accurate measurement of growth occurred after resazurin incubation for 6 hours, without EDTA-mediated permeabilization, and was correlated with the number of cells seeded and sarcosphere volume for 143B (Spearman's r: 0.98; p < 0.001), MG-63.3 (0.99; p < 0.001), and LM7 (0.98; p < 0.001). Sarcospheres met established criteria for screening applications as mean Z' factors were greater than 0.5 for all cell lines. Response to MAP therapy was cell line-dependent, because MG-63.3 and LM7 sarcospheres exhibited greater than 2000-fold resistance to methotrexate (GIC50 = 88 ± 36 μmol/L and 174 ± 16 μmol/L, respectively) compared with the 143B cell line (GIC50 = 0.04 ± 0.01 μmol/L; p < 0.001 for MG-63.3 and LM7). MG-63.3 monolayers were more sensitive to methotrexate (GIC50 = 0.01 ± 0.01 μmol/L; p < 0.001) than MG-63.3 sarcospheres, whereas LM7 monolayers remained chemoresistent (GIC50 not reached). CONCLUSIONS: This study developed and validated a drug screening platform for progression of osteosarcoma micrometastases. It also highlights heterogeneity among osteosarcoma cell lines. These findings appear to reflect known patient-to-patient heterogeneity and underscore the importance of evaluating multiple tumor models when testing drugs for the treatment of osteosarcoma. CLINICAL RELEVANCE: The described approach is a promising starting point for drug screening in osteosarcoma because it is tailored to evaluate micrometastatic disease. A reliable and rapid method to identify novel therapeutics is critical to improve stagnant outcomes for patients with osteosarcoma.
引用
- Collier CD, Wirtz EC, Knafler GJ, et al. Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines. Clin Orthop Relat Res. 2018. PMID: 29481344. doi:10.1007/s11999.0000000000000059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。